Skip to main content

Table 4 Adverse events and adverse drug reactions

From: An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome

 

pAT

AT gamma

N = 113

N = 108

AEs, n (%)

99 (87.6)

89 (82.4)

 AEs that led to death

22 (19.5)

10 (9.3)

 Other serious AEs

7 (6.2)

14 (13.0)

ADRs, n (%)

16 (14.2)

24 (22.2)

 ADRs that led to death

0 (0)

2 (1.9)

 Other serious ADRs

1 (0.9)

3 (2.8)

  1. ADR adverse drug reaction, AE adverse event, pAT plasma-derived antithrombin
Back to article page

Journal of Intensive Care

ISSN: 2052-0492